TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has osteoarthritis of the knee and primary source of pain is knee~* Females must not be pregnant or nursing and must agree to use birth control throughout the study~* Is willing to limit alcohol and caffeine intake~* Is willing to abstain from smoking during study visits~* Must be able to walk on a treadmill at a pace of at least 1 mile/hour~Exclusion Criteria:~* Has a medical/arthritic disease that would interfere with evaluation~* Is unable to take naproxen or Ultracet~* Has congestive heart failure or angina~* Has a history of stroke~* Has a history of uncontrolled high blood pressure~* Has a history of cancer~* Regularly uses a walker or cane

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo, Naproxen, Ultracet (Type: EXPERIMENTAL): Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Naproxen, Ultracet, Placebo (Type: EXPERIMENTAL): Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Ultracet, Placebo, Naproxen (Type: EXPERIMENTAL): Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Placebo, Ultracet, Naproxen (Type: EXPERIMENTAL): Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Naproxen, Placebo, Ultracet (Type: EXPERIMENTAL): Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
- Ultracet, Naproxen, Placebo (Type: EXPERIMENTAL): Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients at least one 1year of age and weighing more than 10kg.~* Microscopic confirmation of P. falciparum and /or P.vivax infection (any parasitaemia).~* Fever (axillary temperature \>37.5C) or history of fever in the last 48 hours.~* Able to participate in the trial and comply with the clinical trial protocol~* Written informed consent to participate in trial; verbal consent in presence of literate witness is required for illiterate patients, and written consent from parents/guardian for children below age of consent~Exclusion Criteria:~* Pregnancy or lactation~* Inability to tolerate oral treatment~* Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral treatment (See Appendix II)~* Known hypersensitivity or allergy to artemisinin derivatives~* Serious underlying disease (cardiac, renal or hepatic)~* Parasitaemia \>4%

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subject of any race, aged 12 to 35 years inclusive~2. Subject weighing between 50 and 110 kg~3. Subject with severe acne (IGA at least 4), which in the opinion of the investigator is appropriate for treatment with oral isotretinoin (severe nodular acne, severe inflammatory acne, recalcitrant acne; all unresponsive to conventional first line therapies)~4. Subject with at least 5 nodules on the face~Exclusion Criteria:~1. Subject with clinically abnormal results to blood testings performed at screening~2. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks~3. Female subject who is pregnant, nursing or planning a pregnancy during the study~4. Subject with known history of hepatic and/or renal insufficiency, to be confirmed by blood testings~5. Subject with known metabolic or structural bone disease (for 12-17 years old population)~6. Subject with bowel disease and/or with hypervitaminosis A~7. Subject who presents with treated or untreated depression or has a history of depression including a family history of major depression~8. Subject with a wash-out period from baseline for topical treatment on the face less than : Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months)~9. Subject with a wash-out period from baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks),Progesterone for contraception (3 months); Spironolactone(3 months); Other acne treatments (6 months);Cyproterone acetate(6 months)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Epiduo/Tactuo + doxycycline 200mg (Type: EXPERIMENTAL): None
- Isotretinoin + vehicle gel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with rheumatoid arthritis (RA) based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria for ≥ 3 months.~* Subjects must have been receiving oral or parenteral methotrexate (MTX) therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to initiating the study drug. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to initiating the study drug. Subjects should continue with their stable doses of MTX and folic acid throughout the study~* Subjects have been treated with 1 or more anti-tumor necrosis factor (TNF) biologics (no maximum cap) for ≥ 3 months but continue to exhibit active RA, or had to discontinue due to intolerability or toxicity. In addition, subjects with prior exposure to non-anti-TNF biologic(s) (no maximum cap) (e.g., abatacept, rituximab, anakinra, or tocilizumab) are allowed.~* Have active RA as defined by the following minimum disease activity criteria: ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline, ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline, high sensitivity C reactive protein (hs-CRP) \> Upper Limit of Normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibody.~Exclusion Criteria:~* Prior exposure to Janus Activated Kinase (JAK) inhibitor (e.g. tofacitinib, baricitinib)~* Pregnant or breastfeeding female~* Ongoing or active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo twice daily (BID) for 12 weeks.
- ABT-494 3 mg BID (Type: EXPERIMENTAL): ABT-494 3 mg twice daily (BID) for 12 weeks.
- ABT-494 6 mg BID (Type: EXPERIMENTAL): ABT-494 6 mg twice daily (BID) for 12 weeks.
- ABT-494 12 mg BID (Type: EXPERIMENTAL): ABT-494 12 mg twice daily (BID) for 12 weeks.
- ABT-494 18 mg BID (Type: EXPERIMENTAL): ABT-494 18 mg twice daily (BID) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven systemic untreated AL amyloidosis requiring systemic chemotherapy~* Not eligible for or refused HDM~* Measurable plasma cell disease~* Life expectancy \> 3 months~* WHO performance status \< 3~* NYHA \< stage IV~* Understand and voluntarily sign an informed consent form~* Laboratory test results within these ranges Absolute neutrophil count \> 1.5 x 109/L Platelet count \> 100 x 109/L Creatinine Clearance / MDRD \> 40 ml/min Total bilirubin \> 2,5 mg/dL~* Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.~Exclusion Criteria:~* Multiple Myeloma stage II and III (Durie and Salmon)~* Previous organ transplantation~* Not able to visit the Amyloid Clinic in Heidelberg once per month~* Refusal of aspiration of 100 ml bone marrow at study inclusion~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.~* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~* Use of any other experimental drug or therapy within 28 days of baseline.~* Known hypersensitivity to thalidomide.~* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* Any prior use of lenalidomide.~* Concurrent use of other anti-cancer agents or treatments.~* Known positive for HIV or infectious hepatitis, B or C.~* Patients who are in a depending position of the Sponsor or the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Treatment Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Hodgkin lymphoma~* FSH and LH levels in peripheral blood below 15 IU/l~* fertile age from 18 to 35 years~* female~* presence of both ovaries~Exclusion Criteria:~* ovarian tumours or cysts over 40 mm in diameter

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- case group (Type: EXPERIMENTAL): Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
- control group (Type: NO_INTERVENTION): no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age with a diagnosis of facial seborrhoeic dermatitis~Exclusion Criteria:~* taking other systemic or topical treatments for facial seborrhoeic dermatitis within the previous 4 weeks~* a known allergy to the components of tacrolimus ointment~* malignant neoplasm; immunologic abnormality~* active infection~* other definitive cutaneous findings such as erythroderma, acne, and psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vehicle twice weekly (Type: NO_INTERVENTION): None
- tacrolimus once weekly (Type: EXPERIMENTAL): None
- tacrolimus twice weekly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis~* Male and female subjects, aged at least 18 years, with newly-diagnosed or relapsed associated vasculitis (AAV) where treatment with cyclophosphamide or rituximab is needed; where approved by Regulatory Agencies, adolescents (12-17 year old) may be enrolled~* Use of adequate contraception~* Positive test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO)~* At least 1 major item, or at least 3 non-major items, or at least the 2 renal items of proteinuria and hematuria on Birmingham Vasculitis Activity Score (BVAS)~* Estimated glomerular filtration rate ≥15 mL/minute/1.73 m\^2 at screening~Exclusion Criteria:~* Pregnant or breast-feeding~* Alveolar hemorrhage requiring pulmonary ventilation support at screening~* Any other known multi-system autoimmune disease~* Required dialysis or plasma exchange within 12 weeks prior to screening~* Have a kidney transplant~* Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1~* Received intravenous glucocorticoids, \>3000 mg methylprednisolone equivalent, within 4 weeks prior to screening~* Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening~* Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count \> 0.01x10\^9/L); received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening~* For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, active infection (especially varicella zoster infection), or platelet count \<50,000/μL before start of dosing~* Participated previously in a CCX168 study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone group (Type: ACTIVE_COMPARATOR): Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
- Avacopan group (Type: EXPERIMENTAL): Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - Histologically confirmed locally advanced or metastatic thyroid cancer - Measurable disease - Normal blood pressure (if history of hypertension, blood pressure must be controlled with medication) - Evidence of disease progression within 6 months before starting study (for differentiated thyroid cancer subjects) - Evidence of disease progression within 6 months before starting study OR symptomatic disease (for medullary thyroid cancer subjects) - Not a candidate for surgical resection, external beam radiotherapy, radioiodine therapy, or other local therapy - At least 18 years of age Exclusion Criteria: - Undifferentiated/anaplastic thyroid cancer - Untreated or symptomatic brain metastases - Prior malignancy, unless cured with treatment and no evidence of disease for greater than or equal to 3 years before starting study (history of thyroid cancer, in situ cervical cancer, or basal cell cancer of skin are exceptions) - Myocardial infarction or any unstable cardiac condition (e.g., congestive heart failure, unstable angina) within 1 year before starting study - Arterial thrombosis or deep vein thrombosis within 1 year before starting study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or older patients with CAP.~* Patients who were diagnosed as moderate in severity.~Exclusion Criteria:~* Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides.~* Hepatic dysfunction (AST, ALT, total bilirubin \> 3 times institutional normal).~* Severe renal dysfunction (creatinine clearance \< 30 ml/min).~* Patients who have a history of severe heart diseases (4th -degree of NYHA). Patients who have a congenital or sporadic long QT syndrome, or who are received the drugs with reported QT prolongation.~* Severe underlying disease.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Azithromycin switch therapy (switch from intravenous to oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patients with essential hypertension~* Patients with body mass index ≥ 30 kg/m2~Exclusion Criteria~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of Hypertensive encephalopathy or cerebrovascular accident.~Other protocol-defined inclusion exclusion criteria also apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete